SME Times News Bureau | 08 May, 2019
Biotech major Biocon drug
Hulio's commercialisation rights have been extended to global markets
from Europe, said the biotech major on Wednesday.
"Under the
terms of global partnership with Mylan for monoclonal antibodies (like
Hulio), we retain our economic interest in the expanded in-licensing
arrangement to a share of profits from global markets, said the
city-based company in a statement here.
Biocon's drug partner
Mylan N.V. is a global generic and specialty pharmaceuticals firm
registered in the Netherlands, with offices in Britain and a global
research centre in the US.
Hulio, which is used to treat
ulcerative colitis in adults, has been in-licensed to Biocon by Mylan on
approval from the Japan-based Fujifilm Kyowa Kirin Biologics.
Mylan launched Hulio in Europe in October 2018 after the European Commission approved it in September 2018.
"We
are committed to enable patient access to affordable biosimilars and
the partnership accelerates that process," said Biocon spokesperson in
the statement.
